NA Vaccine Institute
Latest round
- Series B
Last raised
- Nov 2021
Total raised
- $14M
Investors
- 10
About NA Vaccine Institute
NA Vaccine Institute is dedicated to developing innovative vaccines and therapeutic solutions to address health challenges.Founded in 2018, NA Vaccine Institute operates from Seoul, South Korea and specializes in vaccine development. The company was founded by Dongho Kim, who serves as the CEO.NA Vaccine Institute focuses on the development of innovative vaccines and therapeutic solutions aimed at addressing various health challenges. Their core product offerings include Nexavant®, an immune enhancer, and PeptoVac®, a vaccine designed to bolster the body's defenses against pathogens. Additionally, the company is advancing anti-cancer therapies utilizing PD1 antibodies and regenerative medicine products like PulmonoVac®, aimed at tissue and organ regeneration. These products target a range of end-users, including healthcare providers, research institutions, and ultimately, patients seeking advanced medical treatments.The revenue model for NA Vaccine Institute is structured around B2B transactions, primarily involving partnerships with healthcare providers and institutions for the distribution of their innovative products. The company may engage in strategic collaborations with pharmaceutical distributors to facilitate access to its flagship products, including Nexavant® and PeptoVac®. Revenue is generated through direct sales to healthcare facilities and research organizations, with an emphasis on establishing long-term agreements that foster sustained use of its therapies. Pricing plans are aligned with industry standards for advanced medical products, ensuring competitive positioning within the market. The company plans to expand its market reach into broader Asian territories by the end of 2023, increasing access to its innovative solutions, particularly in regions with high healthcare needs.
Who invested in NA Vaccine Institute
10 investors across 2 rounds
See all investors in NA Vaccine Institute
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about NA Vaccine Institute
Who invested in NA Vaccine Institute?
NA Vaccine Institute has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has NA Vaccine Institute raised?
NA Vaccine Institute has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did NA Vaccine Institute last raise money?
NA Vaccine Institute's most recent round on record is a Series B, in Nov 2021.
What does NA Vaccine Institute do?
NA Vaccine Institute is dedicated to developing innovative vaccines and therapeutic solutions to address health challenges.
Where is NA Vaccine Institute headquartered?
NA Vaccine Institute is headquartered in Seoul, South Korea.
Which VCs invest in companies like NA Vaccine Institute?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back healthcare specialists companies at NA Vaccine Institute's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series B
Raising like NA Vaccine Institute? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.